Drug firms challenge Brazilian regulator's right to veto patents
This article was originally published in SRA
Executive Summary
Companies are finally set to get legal clarity on one of the biggest causes of contention between the pharma industry and Brazilian authorities. The courts will eventually decide on the legality of the medicine regulator's role in vetoing patent applications after Interfarma, the Brazilian pharmaceutical industry association, filed a suit against regulatory agency ANVISA.